ME01899B - Disupstituisana jedinjenja tetrahidrofuranila kao antagonisti receptora bradikinina- b1 - Google Patents
Disupstituisana jedinjenja tetrahidrofuranila kao antagonisti receptora bradikinina- b1Info
- Publication number
- ME01899B ME01899B MEP-2014-118A MEP11814A ME01899B ME 01899 B ME01899 B ME 01899B ME P11814 A MEP11814 A ME P11814A ME 01899 B ME01899 B ME 01899B
- Authority
- ME
- Montenegro
- Prior art keywords
- denotes
- compounds
- salts
- bases
- organic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (10)
1.Jedinjenja opšte formule I, u kojoj R1 označava grupu izabranu između R2 označava H, Cl ili F i X označava CH ili N, njihove enantiomere, njihove dijastereomere, njihove smješe i njihove soli, a posebno njihove fiziološki prihvatljive soli sa organskim ili neorganskim kiselinama ili bazama.
2.Jedinjenja prema zahtjevu 1, naime jedinjenja opšte formule Ia u kojoj R2 označava H, Cl ili F i X označava CH ili N, njihove enantiomere, njihove dijastereomere, njihove smješe i njihove soli, a posebno njihove fiziološki prihvatljive soli sa organskim ili neorganskim kiselinama ili bazama.
3.Jedinjenja prema zahtjevu 1, naime jedinjenja opšte formule Ib u kojoj R2 označava H, Cl ili F i X označava CH ili N, njihove enantiomere, njihove dijastereomere, njihove smješe i njihove soli, a posebno njihove fiziološki prihvatljive soli sa organskim ili neorganskim kiselinama ili bazama.
4.Jedinjenja prema zahtjevu 1, naime jedinjenja opšte formule Ic u kojoj R2 označava H, Cl ili F i X označava CH ili N, njihove enantiomere, njihove dijastereomere, njihove smješe i njihove soli, a posebno njihove fiziološki prihvatljive soli sa organskim ili neorganskim kiselinama ili bazama.
5.Jedinjenja prema zahtjevu 1, naime jedinjenja opšte formule Id u kojoj R2 označava H, Cl ili F i X označava CH ili N, njihove enantiomere, njihove dijastereomere, njihove smješe i njihove soli, a posebno njihove fiziološki prihvatljive soli sa organskim ili neorganskim kiselinama ili bazama.
6.Jedinjenja prema bilo kom od prethodnih zahtjeva, naime njihove enantiomere, njihove dijastereomere, njihove smješe i njihove soli, a posebno njihove fiziološki prihvatljive soli sa organskim ili neorganskim kiselinama ili bazama.
7.Fiziološki prihvatljive soli jedinjenja prema jednom od prethodnih zahtjeva sa organskim ili neorganskim kiselinama ili bazama.
8.Farmaceutske kompozicije koje sadrže jedinjenje prema jednom od prethodnih zahtjeva, opciono zajedno sa jednim ili više inertnih nosača i/ili rastvarača.
9.Lijekovi koji sadrže jedinjenje prema jednom od zahtjeva od 1 do 7.
10.Jedinjenje prema jednom od zahtjeva 1-7 za primjenu kod akutnog i preventivnog lečenja osteoartritisa, akutnih bolova, visceralnih bolova, neuropatskih bolova, zapaljenskih bolova / bolova posredovanih receptorima, tumorskog bola, bolesti sa glavoboljom, dijabetičarske neuropatije, hroničnih bolova u leđima, astme, hroničnog bronhitisa ili COPD. 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10173489 | 2010-08-20 | ||
| PCT/EP2011/064260 WO2012022795A1 (de) | 2010-08-20 | 2011-08-19 | Disubstituierte tetrahydofuranyl-verbindungen als antagonisten des bradykinin-b1-rezeptors |
| EP11748634.0A EP2606042B1 (de) | 2010-08-20 | 2011-08-19 | Disubstituierte tetrahydofuranyl-verbindungen als antagonisten des bradykinin-b1-rezeptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME01899B true ME01899B (me) | 2014-12-20 |
Family
ID=44510978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2014-118A ME01899B (me) | 2010-08-20 | 2011-08-19 | Disupstituisana jedinjenja tetrahidrofuranila kao antagonisti receptora bradikinina- b1 |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US8937073B2 (me) |
| EP (1) | EP2606042B1 (me) |
| JP (1) | JP5727011B2 (me) |
| KR (1) | KR101822371B1 (me) |
| CN (1) | CN103068817B (me) |
| AP (1) | AP2012006630A0 (me) |
| AR (1) | AR082507A1 (me) |
| AU (1) | AU2011290727B2 (me) |
| BR (1) | BR112013003752A2 (me) |
| CA (1) | CA2807086A1 (me) |
| CL (1) | CL2013000310A1 (me) |
| CO (1) | CO6680689A2 (me) |
| CY (1) | CY1115933T1 (me) |
| DK (1) | DK2606042T3 (me) |
| EA (1) | EA022787B1 (me) |
| EC (1) | ECSP13012495A (me) |
| ES (1) | ES2525296T3 (me) |
| GE (1) | GEP20146196B (me) |
| HR (1) | HRP20141172T1 (me) |
| IL (1) | IL224039A (me) |
| MA (1) | MA34578B1 (me) |
| ME (1) | ME01899B (me) |
| MX (1) | MX352548B (me) |
| MY (1) | MY156233A (me) |
| NZ (1) | NZ607435A (me) |
| PE (1) | PE20130810A1 (me) |
| PH (1) | PH12013500330A1 (me) |
| PL (1) | PL2606042T3 (me) |
| PT (1) | PT2606042E (me) |
| RS (1) | RS53622B1 (me) |
| SG (1) | SG187835A1 (me) |
| SI (1) | SI2606042T1 (me) |
| TW (1) | TWI548632B (me) |
| UA (1) | UA108765C2 (me) |
| UY (1) | UY33565A (me) |
| WO (1) | WO2012022795A1 (me) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007034620A1 (de) * | 2007-07-25 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue B1-Antagonisten |
| CL2008002545A1 (es) | 2007-08-29 | 2009-10-23 | Boehringer Ingelheim Int | Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor. |
| US8937073B2 (en) | 2010-08-20 | 2015-01-20 | Boehringer Ingelheim International Gmbh | Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists |
| EP3200589B1 (en) | 2014-09-10 | 2026-03-11 | Temple University Of The Commonwealth System Of Higher Education | Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use |
| US20180221365A1 (en) * | 2015-05-12 | 2018-08-09 | Temple University-Of The Commonwealth System Of Higher Education | Novel sigma-2 receptor binders and their method of use |
| WO2021198534A1 (en) | 2020-04-04 | 2021-10-07 | Oxurion NV | Plasma kallikrein inhibitors for use in the treatment of coronaviral disease |
| US11401303B2 (en) * | 2020-06-15 | 2022-08-02 | Taian City Qihang Biotechnology Co. | Synthetic peptide BRAP and application in preparation of anti-inflammatory drug for COVID-19 thereof |
| WO2023148016A1 (en) | 2022-02-04 | 2023-08-10 | Oxurion NV | Biomarker for plasma kallikrein inhibitor therapy response |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60303441T2 (de) | 2002-02-08 | 2006-09-21 | Merck & Co., Inc. | N-biphenylmethylaminocycloalkancarboxamid-derivative |
| TWI259079B (en) | 2002-02-08 | 2006-08-01 | Merck & Co Inc | N-biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives |
| IL166426A0 (en) * | 2002-08-29 | 2006-01-15 | Merck & Co Inc | N-biarylmethyl aminocycloalkanecarboxamide derivatives |
| CN1832922A (zh) * | 2003-08-07 | 2006-09-13 | 默克公司 | 磺酰基取代的n－(联芳基甲基)氨基环丙烷甲酰胺类 |
| US7332499B2 (en) | 2003-08-07 | 2008-02-19 | Merck & Co., Inc. | Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides |
| CA2557858A1 (en) * | 2004-03-02 | 2005-09-15 | Merck & Co., Inc. | Amino cyclopropane carboxamide derivatives as bradykinin antagonists |
| US20060173023A1 (en) | 2005-02-01 | 2006-08-03 | Wood Michael R | 2-(Bicyclo)alkylamino-derivatives as mediators of chronic pain and inflammation |
| WO2008033564A1 (en) * | 2006-09-15 | 2008-03-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
| HUP0600809A3 (en) * | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
| DE102007034620A1 (de) | 2007-07-25 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue B1-Antagonisten |
| EP2025675A1 (de) | 2007-08-14 | 2009-02-18 | Boehringer Ingelheim International GmbH | Arylsulfonamide mit analgetischer Wirkung |
| CL2008002545A1 (es) * | 2007-08-29 | 2009-10-23 | Boehringer Ingelheim Int | Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor. |
| AR068509A1 (es) | 2007-09-19 | 2009-11-18 | Jerini Ag | Antagosnistas del receptor de bradiquinina b1 |
| WO2010057899A1 (de) | 2008-11-20 | 2010-05-27 | Boehringer Ingelheim International Gmbh | Cykloalkylaminocarbonylderivate als bradykinin-b1-rezeptor antagonisten |
| PT2401256E (pt) | 2009-02-26 | 2013-05-13 | Boehringer Ingelheim Int | Compostos como antagonistas da bradicinina b1 |
| WO2010097374A1 (de) | 2009-02-26 | 2010-09-02 | Boehringer Ingelheim International Gmbh | Verbindungen als bradykinin-b1-antagonisten |
| MA34008B1 (fr) | 2010-02-23 | 2013-02-01 | Boehringer Ingelheim Int | Composes en tant qu'antagonistes de la bradykinine b1 |
| US8586604B2 (en) | 2010-08-20 | 2013-11-19 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin E2 synthase-1 |
| US8901127B2 (en) | 2010-08-20 | 2014-12-02 | Boehringer Ingelheim International Gmbh | Pyridazin derivatives as antagonists of the bradykinin B1 receptor |
| US8759537B2 (en) | 2010-08-20 | 2014-06-24 | Boehringer Ingelheim International Gmbh | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents |
| RU2013111971A (ru) | 2010-08-20 | 2014-09-27 | Аллерган, Инк. | Соединения, действующие на множественные рецепторы простагландина, дающие общую противовоспалительную реакцию |
| US8937073B2 (en) | 2010-08-20 | 2015-01-20 | Boehringer Ingelheim International Gmbh | Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists |
-
2011
- 2011-08-12 US US13/208,567 patent/US8937073B2/en active Active
- 2011-08-19 UA UAA201303313A patent/UA108765C2/uk unknown
- 2011-08-19 SI SI201130320T patent/SI2606042T1/sl unknown
- 2011-08-19 NZ NZ607435A patent/NZ607435A/en not_active IP Right Cessation
- 2011-08-19 KR KR1020137004077A patent/KR101822371B1/ko not_active Expired - Fee Related
- 2011-08-19 DK DK11748634.0T patent/DK2606042T3/da active
- 2011-08-19 WO PCT/EP2011/064260 patent/WO2012022795A1/de not_active Ceased
- 2011-08-19 UY UY0001033565A patent/UY33565A/es not_active Application Discontinuation
- 2011-08-19 ES ES11748634.0T patent/ES2525296T3/es active Active
- 2011-08-19 HR HRP20141172AT patent/HRP20141172T1/hr unknown
- 2011-08-19 CA CA2807086A patent/CA2807086A1/en not_active Abandoned
- 2011-08-19 BR BR112013003752A patent/BR112013003752A2/pt not_active IP Right Cessation
- 2011-08-19 ME MEP-2014-118A patent/ME01899B/me unknown
- 2011-08-19 CN CN201180039753.8A patent/CN103068817B/zh not_active Expired - Fee Related
- 2011-08-19 AR ARP110103036A patent/AR082507A1/es not_active Application Discontinuation
- 2011-08-19 JP JP2013524457A patent/JP5727011B2/ja active Active
- 2011-08-19 AU AU2011290727A patent/AU2011290727B2/en not_active Ceased
- 2011-08-19 MY MYPI2013000537A patent/MY156233A/en unknown
- 2011-08-19 GE GEAP201113031A patent/GEP20146196B/en unknown
- 2011-08-19 SG SG2013010764A patent/SG187835A1/en unknown
- 2011-08-19 PT PT117486340T patent/PT2606042E/pt unknown
- 2011-08-19 MA MA35624A patent/MA34578B1/fr unknown
- 2011-08-19 EA EA201201662A patent/EA022787B1/ru not_active IP Right Cessation
- 2011-08-19 RS RS20140551A patent/RS53622B1/sr unknown
- 2011-08-19 TW TW100129857A patent/TWI548632B/zh active
- 2011-08-19 PL PL11748634T patent/PL2606042T3/pl unknown
- 2011-08-19 EP EP11748634.0A patent/EP2606042B1/de active Active
- 2011-08-19 PH PH1/2013/500330A patent/PH12013500330A1/en unknown
- 2011-08-19 AP AP2012006630A patent/AP2012006630A0/xx unknown
- 2011-08-19 MX MX2013001965A patent/MX352548B/es active IP Right Grant
- 2011-08-19 PE PE2013000265A patent/PE20130810A1/es not_active Application Discontinuation
-
2012
- 2012-12-31 IL IL224039A patent/IL224039A/en active IP Right Grant
-
2013
- 2013-01-30 CL CL2013000310A patent/CL2013000310A1/es unknown
- 2013-02-28 CO CO13041062A patent/CO6680689A2/es active IP Right Grant
- 2013-03-15 EC ECSP13012495 patent/ECSP13012495A/es unknown
-
2014
- 2014-11-26 CY CY20141100985T patent/CY1115933T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2970216T1 (en) | Biaryl-amide compounds as kinase inhibitors | |
| EA201190235A1 (ru) | Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750 | |
| EA201100136A1 (ru) | 2,4'-бипиридинилы в качестве ингибиторов протеинкиназы d, применимые для лечения сердечной недостаточности и рака | |
| EA201170772A1 (ru) | Органические соединения | |
| EP3483143A8 (en) | Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer | |
| EA201101209A1 (ru) | Соединения в качестве антагонистов брадикинина b1 | |
| MX2009008953A (es) | Compuestos como inhibidores de angiogenesis. | |
| BR112014028954A2 (pt) | amidas de n-piridinila substituídas no anel como inibidores da quinase | |
| MX2009009843A (es) | Compuestos espiro sustituidos como inhibidores de la angiogenesis. | |
| EP4219465A3 (en) | Prmt5 inhibitors and uses thereof | |
| ATE522249T1 (de) | Organische verbindungen | |
| MX354102B (es) | Derivados de bencimidazol-prolina. | |
| PT2310356E (pt) | Derivados de adamantildiamida e a sua utilização | |
| HRP20141172T1 (hr) | Disupstituirani spojevi tetrahidrofuranila kao antagonisti receptora bradikinina b1 | |
| MX360330B (es) | Regimen de administracion para nitrocatecoles. | |
| WO2013040227A3 (en) | Therapeutic compounds | |
| HRP20210537T1 (hr) | Upotreba inhibitora faktora induciranog hipoksijom | |
| EA201291014A1 (ru) | Трициклическое индазольное соединение, способ его получения и содержащая его фармацевтическая композиция | |
| EA201070543A1 (ru) | Новые 4-(тетразол-5-ил) хиназолиновые производные в качестве противораковых средств | |
| TW200800993A (en) | Organic compounds | |
| GB0525069D0 (en) | Organic compounds | |
| UY33279A (es) | Una pirimidina sustituida como un antagonista del receptor de la prostaglandina d2 | |
| EA201000882A1 (ru) | Соединение, его применение и фармацевтическая композиция, содержащая это соединение | |
| ECSP11011150A (es) | Derivados de arilciclopropilacetamida útiles como activadores de glucoquinasa | |
| WO2013074905A3 (en) | Compounds, compositions, pharmaceutical compositions, and methods of use |